<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The use of radiofrequency ablation (RFA) for the management of <z:hpo ids='HP_0004755'>supraventricular tachycardia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e>) in infants and small children remains controversial </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to evaluate the safety and efficacy of RFA in <z:e sem="disease" ids="C0010340" disease_type="Disease or Syndrome" abbrv="">critically ill</z:e> small children (&lt;1 year of age) with drug-resistant <z:hpo ids='HP_0001649'>tachycardia</z:hpo> accompanied by arrhythmogenic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> and <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The study included 15 patients age 5.3 ± 3.7 months </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0001716'>Wolff-Parkinson-White syndrome</z:hpo> and atrial <z:hpo ids='HP_0001649'>tachycardia</z:hpo> were detected in eight (53.3 %) and seven (46.7 %) of patients, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with structural heart pathology, including <z:hpo ids='HP_0002564'>congenital heart diseases</z:hpo> and laboratory-confirmed <z:mp ids='MP_0001856'>myocarditis</z:mp>, were excluded from the study </plain></SENT>
<SENT sid="5" pm="."><plain>Indications for RFA included drag-refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> accompanied by arrhythmogenic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> and <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Unsuccessful ablation was observed in two 1-month-old patients who underwent successful ablation 3 months later </plain></SENT>
<SENT sid="7" pm="."><plain>The follow-up period ranged from 0.5 to 8 years (average 3.9) </plain></SENT>
<SENT sid="8" pm="."><plain>Only one patient (6.7 %) had <z:hpo ids='HP_0001649'>tachycardia</z:hpo> recurrence 1 month after RFA </plain></SENT>
<SENT sid="9" pm="."><plain>The short- and long-term RFA success rates were 86.7 and 93.3 %, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>The study did not show any procedure-related complications </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0001635'>Heart failure</z:hpo> disappeared within 5-7 days </plain></SENT>
<SENT sid="12" pm="."><plain>Complete normalization of heart chamber sizes was documented within 1 month after effective RFA </plain></SENT>
<SENT sid="13" pm="."><plain>A three-dimensional CARTO system (Biosense Webster, Inc., USA) was used in three patients with body weight &gt;7 kg </plain></SENT>
<SENT sid="14" pm="."><plain>The use of the CARTO system resulted in a remarkable decrease of the fluoroscopy time without vascular injury or other procedure-related complications in <z:hpo ids='HP_0000001'>all</z:hpo> cases </plain></SENT>
<SENT sid="15" pm="."><plain>Our study suggests that RFA may be considered the method of choice for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> treatment in small children when drug therapy is ineffective and arrhythmogenic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> progresses </plain></SENT>
</text></document>